Detailed Information

Cited 83 time in webofscience Cited 90 time in scopus
Metadata Downloads

Multimodal selenium nanoshell-capped Au@mSiO(2) nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer

Authors
Ramasamy, ThiruganeshRuttala, Hima BinduSundaramoorthy, PasupathiPoudel, Bijay KumarYoun, Yu SeokKu, Sae KwangChoi, Han-GonYong, Chul SoonKim, Jong Oh
Issue Date
11-Apr-2018
Publisher
NATURE PUBLISHING GROUP
Citation
NPG ASIA MATERIALS, v.10, pp.197 - 216
Journal Title
NPG ASIA MATERIALS
Volume
10
Start Page
197
End Page
216
URI
https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3868
DOI
10.1038/s41427-018-0034-5
ISSN
1884-4049
Abstract
Multimodal therapeutic agents based on novel nanomaterials for multidrug resistance have attracted increasing attention in cancer therapy. In this study, we describe the construction of a programmed mesoporous silica-capped gold nanorod covered with nano-selenium overcoat (Se@Au@mSiO(2)) nanoparticles as a multifunctional nanoplatform to incorporate materials with specific chemotherapeutic, chemoprevention, and photoablation/hyperthermia functions that collectively contribute to enhance anticancer efficacy in multidrug-resistant breast cancer. The triple-combination-based nanosized Se@Au@mSiO(2)/DOX effectively accumulates in the tumor and the release of the therapeutic cargo could be remotely manipulated by mild near-infrared (NIR) irradiation. Se@Au@mSiO(2)/DOX notably enhances the cell killing effect through induction of cell apoptosis. In addition, Se@Au@mSiO(2)/DOX inhibits tumor cell growth through cell cycle arrest and induction of apoptosis via suppression of the Src/FAK/AKT signaling pathways. Synergistic Se-photothermal-chemotherapy combination exhibits significant tumor growth suppression and delayed tumor progression in vivo. Immunohistochemistry analysis shows elevated numbers of caspase-3 and PARP-immunolabeled cells and decreased Ki-67 + and CD31 + cancer cells in the tumor mass. No noticeable signs of organ damage or toxicity are observed after treatment with Se@Au@mSiO2/DOX (NIR+), which is further supported by hematology and biochemical analyses. Thus, Se@Au@mSiO2/DOX has potential for the clinical treatment of metastatic breast cancers with little or no adverse effects.
Files in This Item
There are no files associated with this item.
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE